Download PDF
Nuklearmedizin 1976; 15(06): 273-281
DOI: 10.1055/s-0038-1624976
Originalarbeiten — Original Articles
Schattauer GmbH

Knochenaffine radioaktive Substanzen in der Nuklearmedizin

Gertrude Pfeiffer
1   Aus dem Eidg. Institut für Reaktorforschung, Abteilung Isotopenproduktion (H. Hügli), Würenlingen
› Author Affiliations
Further Information

Publication History

Eingegangen:10 April 1976

Publication Date:
10 January 2018 (online)

  PDF Download  Permissions and Reprints

Zusammenfassung

Der Begriff der Knochenaffinität eines radioaktiven Tracers wird aus theoretischen Überlegungen entwickelt und an Hand der verschiedenen, in der nuklearmedizinischen Skelettdiagnostik verwendeten Substanzen diskutiert. Die Aufnahme sehr kurzlebiger Nuklide oder sehr großer Moleküle beweist, daß für die Knochenaffinität der Einbau des Tracers in das Kristallgitter des Apatits kein wesentliches Kriterium ist, da dieser im ersten Fall aus zeitlichen, im zweiten aus räumlichen Gründen nicht möglich ist. Die Fixierung am Knochen ist daher auf unspezifische Adsorptionsvorgänge zurückzuführen.

Für die Eignung eines Tracers in der nuklearmedizinischen Praxis ist neben den physikalischen Eigenschaften des verwendeten Nuklids auch die Ausscheidungskinetik der einzelnen Substanzen zu berücksichtigen, da der nicht im Skelett fixierte Anteil des Tracers für die Qualität der Szintigramme von Bedeutung ist.

Von den verschiedenen Mechanismen, die die Unterschiede in der Anreicherung durch gesunden oder pathologisch veränderten Knochen verursachen, wird besonders die Rolle der Durchblutung diskutiert.

 

  • Literatur

  • 1 Ackerhalt R. E, Blau M, Bakshi S, Sondel J. A. A comparative study of three Tc-labelled phosphorous compounds and F-18-fluoride for skeletal imaging. J. Nucl. Med 1974; 15: 1153.
    PubMedGoogle Scholar
  • 2 Bassett C. A. L, Donath A, Macagno F, Preisig R, Fleisch H. Diphosphonates in the treatment of myositis ossificans. Lancet 1969; II: 845.
    PubMedGoogle Scholar
  • 3 Bauer G. C. H, Wendeberg B. External counting of Ca-47 and Sr-85 in studies of localized skeletal lesions in man. J. Bone Jt. Surg. 41 B. 1959: 558.
    Google Scholar
  • 4 Bisaz S, Fleisch H. pers. Mitteilung.
    Google Scholar
  • 5 Blau M, Ganatra R, Bender M. A. F-18-fluoride for bone imaging. Sem. Nucl. Med. II/1. 1972: 31.
    Google Scholar
  • 6 Bowen B. M, Garnett E. S. Analysis of the relationship between Tc-99m-Sn-polyphosphate and Tc-99m-Sn-pyrophosphate. J. Nucl. Med 1974; 15: 652.
    PubMedGoogle Scholar
  • 7 Buell U, Baiser D, Frey K. W. Vergleichende tierexperimentelle Untersuchungen zur Verteilung von Tc-99m-pyrophosphat, Tc-99m-diphosphonat und Sr-85. Fortschr. Röntgenstr 1974; 120: 481.
    Article in Thieme ConnectGoogle Scholar
  • 8 Chandra R, Braunstein P, Duhov L, Tilbury R.S. Evaluation of Tm-167-HEDTA as a bone scanning agent in humans and its comparison with F-18. Brit. J. Radiol. 47/553. 1974: 51.
    Google Scholar
  • 9 Chiewitz O, Hevesy G. Radioactive indicators in the study of phosphorous metabolism in rats. Nature 1935; 136: 754.
    CrossrefGoogle Scholar
  • 10 Cox P. H. Technetium complexes for skeletal scintigraphy. Physicochemical factors affecting bone and bone marrow uptake. Brit. J. Radiol. 47/564. 1974: 845.
    Google Scholar
  • 11 Creutzig H, Hundeshagen H. Knochenszinti-graphie mit Tc-99m-Polyphosphat und Strontiumradionukliden. Fortschr. Röntgenstr 1973; 119: 560.
    Article in Thieme ConnectGoogle Scholar
  • 12 DeNardo G. L, Jacobsen S. J, Raventos A. Sr-85-bone scan in neoplastic disease. Sem. Nucl. Med. II/1. 1972: 18.
    Google Scholar
  • 13 Dewanjee M. K, Fletcher J. W, Davis M. A. Chemical properties and biologic distribution of Tc-99m-Tin-polyphosphates. J. Nucl. Med 1972; 13: 427.
    Google Scholar
  • 14 Dow E. C, Stanbury J. B. Strontium and calcium metabolism in metabolic bone disease. J. clin. Invest 1960; 39: 885.
    CrossrefPubMedGoogle Scholar
  • 15 Dreyer J, Georgi P, Lorenz W. J, Scheer K. E. Bonescintigraphy with short lived radiopharmaceuticals and computer analysis. Medical radioisotope scintigraphy Vol. II. 1972. IAEA; 327.
    Google Scholar
  • 16 Eckelman W. C, Meinken G, Richards P. The chemical state of Tc-99m in biomedical products. J. Nucl. Med 1972; 13: 577.
    PubMedGoogle Scholar
  • 17 Eckelman W. C, Reba R. C, Kubota H, Stevenson J. S. Tc-99m-pyrophosphate for bone imaging. J. Nucl. Med 1974; 15: 279.
    PubMedGoogle Scholar
  • 18 Fels I. G, Kaplan E, Greco J, Veatch R. Incorporation in vivo of P-32 from condensed phosphates. Proc. Soc. exp. Biol. Med 1959; 100: 53.
    CrossrefPubMedGoogle Scholar
  • 19 Firusian N. Kinetik des Radiostrontium. Nucl.-Med. XIII/2. 1974: 127.
    Google Scholar
  • 20 Fleisch H, Neuman W. F. Mechanism of calcification: role of collagen, polyphosphates and phosphatase. Amer. J. Physiol 1961; 200: 1296.
    PubMedGoogle Scholar
  • 21 Fleisch H, Russell R. G. G, Bisaz S, Bonjour J. P. The effects of pyrophosphate and diphosphonates on calcium metabolism. Hard Tissue Growth. CIBA Symposion 11. 1973
    Google Scholar
  • 22 Fleisch H, Russell R. G. G, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212: 901.
    CrossrefPubMedGoogle Scholar
  • 23 Genant H. K, Bautovich G. J, Singh M, Lathrop K. A, Harper P.V. Bone-seeking radionuclides: an in vivo study of factors affecting skeletal uptake. Radiology 1974; 113: 373.
    CrossrefPubMedGoogle Scholar
  • 24 Georgi P, Lorenz J. W. Knochenszintigraphie mit digitaler Datenverarbeitung. Radiobiol. Radiother. XV/1. 1974: 155.
    Google Scholar
  • 25 Georgi P, Sinn H, Matzku S, Maier-Borst W, Bahk Y. W. Tierexperimentelle Untersuchungen zur Knochenszintigraphie. Nuclearmedizin IX. 194 1970
    Google Scholar
  • 26 Gorski B, Koch H. Zur Chemie des Technetiums in wässriger Lösung-J. Inorgan. Nucl. Chem 1969; 31: 3565.
    Google Scholar
  • 27 Harrison G. E, Carr T. E. F, Sutton A. Distribution of radioactive calcium, strontium, barium and radium following intravenous injection into a healthy man. Int. J. Radiat. Biol. 13/3. 1967: 235.
    Google Scholar
  • 28 Hegesippe M, Beydon J, Bardy A, Panneciere et C. Trousse singlestep de pyrophosphate d’etain marqué au technétium-99m pour scintigraphic osseuse. Radiopharmaceuticals and labelled compounds. Vol. I. 1973. IAEA; 109.
    Google Scholar
  • 29 Hosain P. Technetium-99m labelled pyrophosphate: a simple and reproducible bone scanning agent. Brit. J. Radiol. 46/549. 1973: 724.
    Google Scholar
  • 30 Jowsey J, Riggs B. L. Assessment of bone turnover by microradiography and autoradiography. Sem. Nucl. Med. II/1. 1972: 3.
    Google Scholar
  • 31 Jowsey J, Rowland R. E, Marshall J. H. The deposition of the rare earths in bone. Radiat. Res 1958; 8: 490.
    CrossrefPubMedGoogle Scholar
  • 32 Kaplan E, Fels I. G, Kotlowski B. R, Greco J, Walsh W. S. Therapy of carcinoma of the prostate metastatic to bone with P-32-labelled condensed phosphate. J. Nucl. Med 1960; 1: 1.
    Google Scholar
  • 33 Kaye M, Silverton S, Rosenthall L. Technetium-99m-labelled pyrophosphate: studies in vivo and in vitro. J. Nucl. Med 1975; 16: 40.
    PubMedGoogle Scholar
  • 34 King A. G, Hupf H. B, Block R. E. Polyphosphates: a chemical analysis of average chain length and the relationship to bone deposition in rats. J. Nucl. Med 1973; 14: 695.
    PubMedGoogle Scholar
  • 35 Krishnamurthy G. T, Tubis M, Endow J. S, Singhi V, Walsh C. F, Blahd W. H. Clinical comparison of the kinetics of Tc-99m labelled polyphosphate and diphosphonate. J. Nucl. Med 1974; 15: 848.
    PubMedGoogle Scholar
  • 36 Levin V. L, Tarasov N. F, Kurtshatova L. N, Malinin A. B, Kurenkov N. V, Basura N. A, Arsentyeva R. P. Ba-133m production and a study of its application to bone scanning. Isotopenpraxis 1974; 10: 182.
    CrossrefGoogle Scholar
  • 37 McLean F. C, Bunday A. M. Radiation, Isotopes and Bone. Academic Press; 1974
    Google Scholar
  • 38 Maier-Borst W, Sinn H. F-18-Komplexverbindun-gen für die Knochenszintigraphie. Nucl.-Med. VII. 1968: 396.
    Google Scholar
  • 39 Mesmer R. E, Irani R. R. Metal complexing by phosphorous compounds. VIII complexing of tin (II) by polyphosphates. J. Inorgan. Nucl. Chem 1966; 28: 493.
    CrossrefGoogle Scholar
  • 40 Nelson M. F, Melton R. E, van Wazer J. R. Sodium trimetaphosphate as a bone-imaging agent. J. Nucl. Med 1975; 16: 1043.
    PubMedGoogle Scholar
  • 41 Neuman W. F, Neuman M. W. The nature of the mineral phase of bone. Chem. Rev 1953; 53: 1.
    CrossrefGoogle Scholar
  • 42 O’Mara R. E, McAfee J. G, Subramanian G. Rare earth nuclides as potential agents for skeletal imaging. J. Nucl. Med 1969; 10: 49.
    PubMedGoogle Scholar
  • 43 O’Mara R. E, Subramanian G. Experimental agents for skeletal scintigraphy. Sem. Nucl. Med. II/1. 1972: 38.
    Google Scholar
  • 44 Pfeiffer G, Huegli H. Vergleich verschiedener Technetium-Zinn-Phosphatverbindungen in vivo und in vitro. Radioaktive Isotope in Klinik und Forschung 1976; 12: 201.
    Google Scholar
  • 45 Quinn III J. L, McCrews M. C, Wester-mann B. R. Tc-99m versus F-18 bone scanning agents: advantages and disadvantages. Radiopharmaceuticals and labelled compounds Vol. I. IAEA; 1973: 119.
    Google Scholar
  • 46 Rao D. V, Goodwin P. N. Pb-203 a potential radionuclide for skeletal imaging. J. Nucl. Med, 1973; 14: 872.
    PubMedGoogle Scholar
  • 47 Rayudu G. V. S, Troutt E. D, Fordham E. W. A comparison of Tc-99m-Tin(II)polyphosphates,Sr-87m and F-18 in bone imaging. J. Nucl. Med 1972; 13: 462.
    Google Scholar
  • 48 Rosoff B, Siegel E, Williams G. L, Spencer H. Distribution and excretion of radioactive rare-earth compounds in mice. Int. J. Appl. Radiol. Isotop 1963; 14: 129.
    Google Scholar
  • 49 Sack H. Nuklearmedizinische Untersuchungen zur Kalziumresorption und zum Knochenstoffwechsel. Radio-biol. Radiother. XV. 1974: 167.
    Google Scholar
  • 50 Schuemichen C, Nakken K. F. A comparison of the bone seeking properties of short chained Tc-99m-Sn-polyphosphates. Nucl.-Med. XIII. 1974: 139.
    Google Scholar
  • 51 Schuemichen C, Roervik-Schuemichen K, Hoffmann G. Tc-99m-Sn-pyrophosphate complexes: an investigation of its possible structure. Nucl.-Med. XIII. 1974: 252.
    Google Scholar
  • 52 Spencer R. P, Lange R. C, Treves S. Use of Ba-135m and Ba-131 as bone scanning agents. J. Nucl. Med 1971; 12: 216.
    PubMedGoogle Scholar
  • 53 Spencer H, Li M, Samachson J, Laszlo D. Metabolism of Strontium-85 and Calcium-45 in man. Metabolism 1960; 9: 916.
    Google Scholar
  • 54 Steinberg M, Rasmussen J. W, Ennow K, Roy-Poulsen N. O, Voetmann V, Poulsen B, Andersen M. L. Tm-167-citrate for bone imaging. Radiopharmaceuticals and labelled compounds Vol. II. IAEA; 1973: 151.
    Google Scholar
  • 55 Stern K. G, Steinberg M. A. Desoxyribonucleic acid complexes of rare earths. Biochem. Biophys. Acta 1953; 11: 553.
    CrossrefPubMedGoogle Scholar
  • 56 Stevenson J. S, Eckelman W. C, Sobocinski P. Z, Reba R. C, Barron E. L, Levin S. G. The toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD-50. J. Nucl.-Med 1974; 15: 252.
    PubMedGoogle Scholar
  • 57 Subramanian G, McAfee J. G. A new complex of Tc-99m for skeletal imaging. Radiology 1971; 99: 192.
    CrossrefPubMedGoogle Scholar
  • 58 Subramanian G, McAfee J. G, Blair R. J, O’Mara R. E. Dy-157-HEDTA for skeletal imaging. J. Nucl. Med 1971; 12: 558.
    PubMedGoogle Scholar
  • 69 Subramanian G, McAfee J. G, O’Mara R. E, Rosenstreich M, Mehter A. Tc-polyphosphate PP46: a new radiopharmaceutical for skeletal imaging. J. Nucl. Med 1971; 12: 399.
    Google Scholar
  • 60 Syed I. B, Hosain F, Wagner H. N. Development of Barium-135m radiopharmaceutical for skeletal imaging. Nucl.-Med. XI. 291 1972
    Google Scholar
  • 61 Tofe A. J, Francis M. D. Optimization of the ratio of stannous tin: ethane-l-hydroxy-l,l-diphosphonate for bone scanning with Tc-99m-pertechnetate. J. Nucl. Med 1974; 15: 69.
    PubMedGoogle Scholar
  • 62 Treadwell A, Low-Beer V. A, Friedell H. L, Lawrence J. H. Metabolic studies on neoplasm of bone with the aid of radioactive strontium. Amer. J. Med. Sci 1942; 204: 521.
    CrossrefGoogle Scholar
  • 63 Vaughan J. M. The physiology of bone. Clarendon Press; 1970
    Google Scholar
  • 64 Weber D. A, Greenberg E. J, Dimich A, Kenny P. J, Rothschild E. O, Myers W. P. L, Laughlin J. S. Kinetics of radionuclides used for bone studies. J. Nucl. Med 1969; 10: 8.
    PubMedGoogle Scholar
  • 65 Wellman H. N, Browne A, Tofe A. J, Francis M. D. Optimisation of a new kit-prepared skeletal imaging agent Tc-99m-Sn-EHDP compared with F-18. Radiopharmaceuticals and labelled compounds Vol. I. IAEA; 1973: 93.
    Google Scholar
  • 66 Yano Y, Chu P, Anger H. O. Tin-117m: production, chemistry and evaluation as a bone scanning agent. Int. J. Appl. Radiat. Isotop 1973; 24: 319.
    CrossrefPubMedGoogle Scholar
  • 67 Yano Y, McRae J, van Dyke D. C, Anger H. O. Technetium-99m-labelled stannous ethane-l-hydroxy-1, 1-diphosphonate: a new bone scanning agent. J. Nucl. Med 1973; 14: 73.
    PubMedGoogle Scholar
  • 68 Yano Y, van Dyke D. C, Verdon T. A, Anger H. O. Cyclotronproduced Dy-157 compared with F-18 bone scanning using the whole body scanner and scintillation camera. J. Nucl. Med 1971; 12: 815.
    PubMedGoogle Scholar